Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell ...

It has announced deals with telehealth companies like Hims & Hers (HIMS), specialty pharmacy deals like the one with Humana's (HUM) CenterWell, as well as Thursday's CVS deal. Read more about Eli ...

The county joins municipalities across the country suing Eli Lilly, CVS Caremark, and others for sky-high prices.

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

The market reaction came as Trump signed a wide-ranging executive order aimed at slashing prescription drug prices in the US.

Shares of Eli Lilly plunged 11% on Thursday. But several Wall Street analysts said the selloff was overblown. "In our view, the Novo/CVS deal does not represent the beginning of an obesity ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

CVS’s formulary now favors Novo’s Wegovy ... Patents, economies of scale, and a powerful distribution network support Eli Lilly’s wide moat. Lilly’s patent-protected drugs carry strong ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...